- $34.87m
- -$145.60m
- $31.37m
Brief: Eyepoint Inc Topline Data For Duravyu In Dme Anticipated In 2H 2027
Brief: Eyepoint Appoints Michael Campbell As Chief Commercial Officer
Brief: Eyepoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Eyepoint Reports Inducement Grants Under NASDAQ Listing Rule
Brief: Eyepoint Pharmaceuticals Changes Name To Eyepoint Inc
Brief: EyePoint announces positive recommendation by Data Safety Monitoring Committee for phase 3 trials for Duravyu
EyePoint Pharma Q3 loss widens
U.S. STOCKS ON THE MOVE-Bank of America, Dollar Tree, Morgan Stanley
U.S. STOCKS ON THE MOVE-Prologis, Winmark, Amphenol
U.S. STOCKS ON THE MOVE-Nvidia, First Horizon, 60 Degrees
U.S. STOCKS ON THE MOVE-AMD, Bank of America, Morgan Stanley
EyePoint Pharma falls on pricing $150 mln stock offering
Brief: Eyepoint Pharmaceuticals Prices Public Offering Of 11 Million Shares At $12.00 Per Share
EyePoint Pharma slips after announcing $150 mln stock offering
Brief: Eyepoint Announces Proposed Public Offering Of Common Stock
Brief: Eyepoint Pharmaceuticals Inc Files For Mixed Shelf Size Not Disclosed - SEC Filing
Brief: Eyepoint Pharmaceuticals Announces Phase 3 Program Initiation For Duravy In Diabetic Macular Edema
Brief: EyePoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
EyePoint Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary